From: PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
Drug | Drug target | Companion antibody clone | Developer | Definition of positive test |
---|---|---|---|---|
Nivolumab | PD-1 | 28-8 | Dako | ≥5 % membranous staining of tumor cells (minimum 100 cells evaluated) |
Bristol-Meyers Squibb | ||||
Pembrolizumab | PD-1 | 22C3 | Dako | ≥1%a membranous staining of tumor cells or immune cells that are intercalating or at the tumor interface |
Merck | ||||
Atezolizumab (MPDL3280A) | PD-L1 | SP142 | Ventana | Each specimen assigned a score based on both tumor and immune cell PD-L1: |
Genentech/Roche | ||||
TC3/IC3 PD-L1 ≥ 50 % | ||||
TC2/IC2 PD-L1 5-49Â % | ||||
TC1/IC1 PD-L1 1-4Â % | ||||
TC0/IC0 PD-L1 < 1 % | ||||
Durvalumab (MEDI4736) | PD-L1 | SP263 | Ventana | ≥25 % membranous staining of tumor cells |
MedImmune/AstraZeneca |